European Shares Rally on Iran Hopes, but AstraZeneca Drags Down FTSE 100

European Stocks Advance as Washington Signals Restraint on Iran

European stock markets closed mostly higher on Monday, with the region-wide Stoxx Europe 600 advancing 0.45% to 652.09 points, as investors bet on a diplomatic path to lower Middle East tensions. The gains were broad across Western Europe: Germany's DAX rose 1.45%, France's CAC 40 climbed 1.22%, Italy's FTSE MIB added 1.34% and Spain's IBEX 35 gained 1.01%. London was the outlier, with the FTSE 100 easing 0.1%.

The main catalyst was a Sunday statement from US President Donald Trump on Truth Social, in which he said he had decided not to carry out planned large-scale strikes on Iran, preferring to try to achieve US goals through peaceful means. Trump said Tehran and other Middle East countries had asked Washington to hold off, and he predicted an agreement related to the Strait of Hormuz would be concluded in the near future. He also cautioned that the US could resume strikes at any time if necessary.

The tone of the session was set by a sharp rise in defense contractor shares: Germany's Hensoldt jumped 8.3%, while Thales climbed 3.2%, Rheinmetall 3.1%, Rolls-Royce 2.7% and BAE Systems 2.3%. Switzerland's Clariant rose 7% after publishing strong quarterly results on Friday, and Siemens Healthineers added 6.1% after improving its annual net profit forecast. In travel, easyJet gained 2% after extending to Aug 7 the deadline for US private equity firm Castlelake to decide on a possible takeover offer. Ryanair and Lufthansa both rose 2.2%, and TUI AG advanced 3.2% as oil prices fell. Oil majors finished mixed: BP slipped 0.1%, Eni fell 1.2%, Equinor lost 1.4%, while Shell gained 0.2% and TotalEnergies was flat.

The biggest drag in the Stoxx 600 and the FTSE 100 was AstraZeneca, whose shares slumped 9% on reports that the company is exploring a combination with US peer Bristol Myers Squibb. Other notable losers included Ipsen (-8.4%), Swedish Orphan Biovitrum (-7.4%), IG Group Holdings (-6.1%) and Teleperformance (-5.9%).

Trade-offs Behind the Rally: Defense, Airlines and a London Drag

Monday's session was less a single risk-on move than a series of sector-specific bets. The common thread was a geopolitical repricing: investors appeared to factor in a lower probability of open US-Iran conflict, a shift that was accompanied by falling oil prices and firmer airline shares. But the day's largest individual moves were driven by company news and positioning.

The Geopolitical Driver: A Hormuz Deal in Sight

Trump's statement reframes the market calculus. A quick agreement on the Strait of Hormuz would reduce the risk of supply disruption through one of the world's most critical oil shipping lanes, which in turn supports equities that suffer when energy costs are high, such as airlines and travel operators. That logic helps explain the gains in Ryanair, Lufthansa and TUI. The caveat is explicit in Trump's post: the US says it can resume strikes at any time, so the geopolitical risk premium has not disappeared — it has been deferred.

Defense and Airlines Rose Together: Two Reasons

At first glance, it looks odd for defense contractors to rally on the same day investors cheered de-escalation. Hensoldt's 8.3% gain, along with advances in Thales, Rheinmetall, Rolls-Royce and BAE Systems, suggests the market sees demand for European defense as driven by multi-year procurement and budget commitments rather than by the immediate conflict alone. It may also reflect hedging: if diplomacy fails, these names benefit. The coexistence of both trends implies investors bought the geopolitical relief while keeping some exposure to conflict beneficiaries — a balanced-risk positioning rather than a clean shift to risk-on.

AstraZeneca's Slide Weighs on London

The FTSE 100's underperformance was almost entirely about stock specifics. AstraZeneca's 9% drop, which the report attributes to news that it is exploring a combination with Bristol Myers Squibb, is enough to weigh on a benchmark where the pharma group is one of the largest constituents. No deal has been confirmed, and the source report does not specify terms, so the negative reaction likely reflects uncertainty about such a large transaction's strategic and financial logic. Other healthcare names such as Ipsen and Swedish Orphan Biovitrum also fell sharply, but no stated connection to the AstraZeneca report links them; their declines may reflect sector rotation or separate news.

Earnings Give Traders Something Concrete

Not all Monday gains were geopolitical. Clariant rose 7% after strong quarterly numbers published Friday, and Siemens Healthineers gained 6.1% after raising its annual net profit forecast. These moves show that with macro headlines in flux, investors are still paying for evidence of operational momentum. Ageas also added 2.2% on news that Malaysia's Maybank will buy a 31% stake in the parent of insurer Etiqa for $1.2 billion.

Key Signals for Investors After Monday's Divergent Close

Investors are now caught between a diplomatic scenario and a military one. The specific variables to weigh this week:

• Watch whether a US-Iran agreement on the Strait of Hormuz materializes. Trump said a deal is expected in the near future, but also said strikes could resume at any time; headlines on either side are likely to move oil prices and airline stocks such as Ryanair, Lufthansa and TUI.
• Track easyJet's takeover timeline: the airline has extended the deadline for US firm Castlelake to decide on its bid to Aug 7, making the stock a near-term corporate event play.
• Treat the AstraZeneca slide as news-driven rather than fundamental until there is official confirmation. The company is reportedly exploring a combination with Bristol Myers Squibb; no terms have been published.
• Assess whether defense names can hold Monday's gains. Hensoldt, Thales, Rheinmetall, Rolls-Royce and BAE Systems rallied between 2.3% and 8.3%, but part of that move could reverse on a confirmed deal.
• Note the divergence in oil majors: BP, Eni and Equinor fell while Shell and TotalEnergies were flat. Lower crude is supportive for travel-related sectors but signals mixed earnings prospects for producers.